BOSTON--(BUSINESS WIRE)--Sep. 6, 2016--
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing
drugs to treat cancer, today announced that the company will present at
the Rodman & Renshaw 18th Annual Global Investment Conference onTuesday, September 13th at 10:25 AM Eastern Time at The Lotte New York
Palace Hotel.
A live audio webcast of the presentation will be available on the
company’s website at www.verastem.com.
An archived presentation will be available for 90 days.
About Verastem, Inc.
Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on
discovering and developing drugs to improve outcomes for patients with
cancer. Our product candidates utilize a multi-faceted approach to treat
cancer by reducing cancer stem cells, enhancing anti-tumor immunity, and
modulating the local tumor microenvironment. Our most advanced clinical
product candidates are the Focal Adhesion Kinase inhibitors, VS-6063 and
VS-4718, and the dual PI3K/mTOR inhibitor, VS-5584. For more
information, please visit www.verastem.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160906005306/en/
Source: Verastem, Inc.
Verastem, Inc.
Brian Sullivan, 781-292-4214
bsullivan@verastem.com
